Table of Content

Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Research and Development
4.1.1.2. Increasing Cases of GBM
4.1.1.3. Market Strategies
4.1.2. Restraints
4.1.2.1. High Research Cost
4.1.2.2. Reoccurrence of GBM
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Forces Analysis
5.2. Epidemiological Analysis
5.3. Research and Developments
5.4. Pipeline Analysis
5.5. Supply Chain Analysis
5.6. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. By Treatment Type
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type Segment
7.1.2. Market Attractiveness Index, By Treatment Type Segment
7.2. Drugs
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.2.2.1. Temozolomide
7.2.2.2. Bevacizumab
7.2.2.3. Carmustine
7.2.2.4. Others
7.3. Immunotherapy
7.4. Electric Field Therapy
7.5. Others
8. By Type of Molecule
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Molecule Segment
8.1.2. Market Attractiveness Index, By Type of Molecule Segment
8.2. Small Molecules
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Biologics
9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment
9.1.2. Market Attractiveness Index, By Route of Administration Segment
9.2. Oral
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Parenteral
10. By End User
10.1. Introduction
10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
10.1.2. Market Attractiveness Index, By End User Segment
10.2. Hospitals and Clinics
10.2.1. Introduction
10.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
10.3. Cancer Treatment Centers
10.4. Others
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Molecule
11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. The U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Molecule
11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. The U.K.
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Molecule
11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Molecule
11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Molecule
11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
12. Competitive Landscape
12.1. Key Developments and Strategies
12.2. Company Share Analysis
12.3. Product Benchmarking
13. Company Profiles
13.1. Pfizer
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Key Highlights
13.1.4. Financial Overview
13.2. Genentech
13.3. Amgen
13.4. Merck & Co., Inc.
13.5. Teva Pharmaceutical Industries, Ltd.
13.6. Arbor Pharmaceuticals LLC.
13.7. Sun Pharmaceutical Industries, Ltd.
13.8. F. Hoffmann-Le Roche AG
13.9. Novartis
LIST NOT EXHAUSTIVE
14. DataM
14.1. Appendix
14.2. About Us and Services
14.3. Contact